Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Gynecol Oncol. 2010 Jun;21(2):93-96. English. Original Article. https://doi.org/10.3802/jgo.2010.21.2.93
Mabuchi S , Morishige K , Enomoto T , Kimura T .
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan. smabuchi@gyne.med.osaka-u.ac.jp
Abstract

OBJECTIVE: The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an initial treatment in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IVb cervical cancer. METHODS: We retrospectively reviewed seven patients with stage IVb cervical cancer who have been primarily treated with TC. The activity and the toxicity were evaluated. Response rate was the main endpoint. RESULTS: Overall, the treatment of TC was well tolerated. The overall response rate was 71.4% (2 complete response, 3 partial response). Although grade 3-4 hematologic toxicities were observed in 3 out of 7 patients (42.8%), no patients experienced grade 3-4 non-hematologic toxicities. When we combined our present results with the previous reports, the overall response rate of TC is 63.6%. CONCLUSION: TC is active and well tolerated in patients FIGO stage IVb cervical cancer. This combination may be considered as an initial treatment regimen in this patient population.

Copyright © 2019. Korean Association of Medical Journal Editors.